Q-omics provides the consensus-scored HELT profile across patient tissues and cancer cell-line models. HELT expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HELT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, HELT RNA expression shows 6,855 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where HELT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HELT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HELT survival associations across molecular data types. HELT RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HELT RNA expression–survival associations across cancer types. High HELT expression shows unfavorable associations in STAD, BLCA, COAD, LIHC and LGG, but favorable associations in LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for HELT RNA expression.
This table summarizes HELT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HELT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HELT shows lower tumor expression in KIRC, KICH, KIRP, LUAD and LUSC and higher tumor expression in BRCA. The KIRC box plot shows higher HELT RNA expression in normal versus tumor tissue (log2 FC = −1.068, t-test p < 0.001).
This table shows molecular features associated with HELT in patient tissues and cancer cell lines. In patient samples, HELT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HELT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
